OPC-214870 / Otsuka - LARVOL DELTA

A Single-blind, Placebo-controlled, Outpatient Trial to Assess the Effects of Single Oral Tablet Dose of OPC-214870 (clinicaltrials.gov) - P1b | N=16 | Completed | Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Recruiting ➔ Completed

Trial completion • CNS Disorders • Epilepsy

A Single-blind, Placebo-controlled, Outpatient Trial to Assess the Effects of Single Oral Tablet Dose of OPC-214870 (clinicaltrials.gov) - P1b; N=16; Recruiting; Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Trial completion date: Mar 2021 ➔ Aug 2021; Trial primary completion date: Mar 2021 ➔ Aug 2021

Clinical • Trial completion date • Trial primary completion date • CNS Disorders • Epilepsy

A Single-blind, Placebo-controlled, Outpatient Trial to Assess the Effects of Single Oral Tablet Dose of OPC-214870 (clinicaltrials.gov) - P1b; N=16; Recruiting; Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Active, not recruiting ➔ Recruiting

Clinical • Enrollment open • CNS Disorders • Epilepsy

A Single-blind, Placebo-controlled, Outpatient Trial to Assess the Effects of Single Oral Tablet Dose of OPC-214870 (clinicaltrials.gov) - P1b; N=16; Active, not recruiting; Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • CNS Disorders • Epilepsy

A Single-blind, Placebo-controlled, Outpatient Trial to Assess the Effects of Single Oral Tablet Dose of OPC-214870 (clinicaltrials.gov) - P1b; N=16; Recruiting; Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Not yet recruiting ➔ Recruiting

Enrollment open

A Single-blind, Placebo-controlled, Outpatient Trial to Assess the Effects of Single Oral Tablet Dose of OPC-214870 (clinicaltrials.gov) - P1b; N=16; Not yet recruiting; Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Clinical • New P1 trial